Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time: March 2, 2022; 5:15 – 9:00 p.m.
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- **Members in attendance:** Stuart Williams, JD; Kelly Ruby, PharmD; Monica Brands, RPh; Kathryn Lombardo, MD; Margaret Artz, RPh, PhD; Kathryn Montag-Shafer, PharmD; Tim Cernohous, PharmD; James Phillips, MD
- **Members absent:** Tsewang Ngodup, MD; Michael Sprehe, MD
- **DHS staff present:** Dave Hoang, PharmD, MBA; Chad Hope, PharmD; Nathan Chomilo, MD
- **Others in attendance:** Ariane Casey, PharmD; Naana Osei-Boateng, PharmD; Umang Patel, PharmD

Report of the Chair

- Stuart Williams presided over the meeting and advised the committee to continue to seek nominations for the Chair position.

Approval of Minutes

- The committee reviewed and accepted the Minutes from the November 2021 meeting as presented.

DHS Housekeeping

Old Business – None

New Business

- Dave Hoang announced that the Spring/Summer DFC meeting would most likely be a hybrid meeting following the recent announcement by Minnesota Management and Budget of the opening of state buildings effective April 22, 2022. We will post the agenda and meeting format on the DFC webpage at least 30 days prior to the meeting.
Existing Specialty Drugs for Continued Prior Authorization (PA)

- The committee discussed Aduhelm and recommended to the Department of Human Services (DHS) by a unanimous vote that Aduhelm remain on PA with the proposed criteria.

- The committee discussed Truseltiq and recommended to DHS by a unanimous vote that Truseltiq remain on PA with the proposed criteria.

- The committee discussed Rylaze and recommended to DHS by a unanimous vote that Rylaze remain on PA with the proposed criteria.

- The committee discussed Kerendia and recommended to DHS by a unanimous vote that Kerendia remain on PA with the proposed criteria.

- The committee discussed Saphnelo and recommended to DHS by a unanimous vote that Saphnelo remain on PA with the proposed criteria.

- The committee discussed Bylvay and recommended to DHS by a unanimous vote that Bylvay remain on PA with the proposed criteria.

- The committee discussed Nexviazyme and recommended to DHS by a unanimous vote that Nexviazyme remain on PA with the proposed criteria, with the following changes:
  
  - Remove 7th bullet point under Initial approval criteria (Patient has documented baseline values for FVC and/or 6MWT).
  - Remove 3rd bullet point under Renewal criteria (Patient has demonstrated a beneficial response to therapy compared to pretreatment baseline in one or more of the following, disease stabilization or improvement in FVC and/or 6MWT).

- The committee discussed Rezurock and recommended to DHS by a unanimous vote that Rezurock remain on PA with the proposed criteria.

- The committee discussed Exkivity and recommended to DHS by a unanimous vote that Exkivity remain on PA with the proposed criteria.

- The committee discussed Tivdak and recommended to DHS by a unanimous vote that Tivdak remain on PA with the proposed criteria.
• The committee discussed Livmarli and recommended to DHS by a unanimous vote that Livmarli remain on PA with the proposed criteria, with the following change:
  
  o Amend 7th bullet point of Initial approval criteria to read: Patient has failed an adequate trial, or is intolerant to, or has a contraindication to at least 2 conventional treatments for the symptomatic relief of pruritis (e.g., ursodeoxycholic acid [ursodiol], cholestyramine, rifampin, naloxone, naltrexone, antihistamine).

• The committee discussed Susvimo and recommended to DHS by a unanimous vote that Susvimo remain on PA with the proposed criteria.

• The committee discussed Scemblix and recommended to DHS by a unanimous vote that Scemblix remain on PA with the proposed criteria.

• The committee discussed Voxzogo and recommended to DHS by a unanimous vote that Voxzogo remain on PA with the proposed criteria, with the following change:
  
  o Amend 8th bullet point under Initial approval criteria to read: Patient has not had limb-lengthening surgery within the previous 18 months.

• The committee discussed Livtencity and recommended to DHS by a unanimous vote that Livtencity remain on PA with the proposed criteria.

Consent Agenda Items

• The committee discussed Hetlioz and Hetlioz LQ under the Consent Agenda Policy and recommended to DHS by a unanimous vote that both items remain on PA with the proposed updated criteria.

Existing Drugs for Continued PA

• The committee discussed Brexafemme and recommended to DHS by a unanimous vote that Brexafemme remain on PA with the proposed criteria, with the following change:
  
  o Amend 4th bullet point to read: patient has tried and failed a trial of oral fluconazole, unless contraindicated for the current episode.

• The committee discussed Vuity and recommended to DHS by a unanimous vote that Vuity remain on PA with the proposed criteria.

Preferred Drug List

• The committee discussed the Acne Agents, Topical Therapeutic Class and recommended the following to DHS by a unanimous vote:
  
  o Remove TAZORAC CREAM (TOPICAL) and TAZORAC GEL (TOPICAL) from the PDL.
Adjournment

- The meeting was adjourned at approximately 8:05 p.m. Central Time.